Altimmune Faces Legal Challenges as Key Clinical Data Approaches

Altimmune finds itself navigating turbulent waters as multiple class-action lawsuits cast a shadow over the company’s stock performance. The litigation alleges the biopharmaceutical firm made misleading statements regarding the efficacy and trial data for its lead drug candidate, pemvidutide.

Investors are facing a critical deadline of October 6, 2025, to register as lead plaintiffs in these consolidated actions. The suits focus on allegedly false statements made between August 2023 and June 2025. Central to the dispute are the topline results from the IMPACT Phase 2b trial, with plaintiffs contending that Altimmune failed to achieve its primary endpoint of fibrosis improvement with statistical significance, attributing this shortfall to an unexpectedly high placebo response.

The market delivered a harsh verdict when these study results... Read more...